Masashi Miyamoto, Kyowa Kirin CEO
Kyowa Kirin pulls the plug on drug development for successor to Parkinson's drug Nourianz
Three years after Japan’s Kyowa Kirin secured FDA approval for an add-on therapy to levodopa in Parkinson’s, the company has scrapped its potential successor. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.